Form PTO 1449 (Modified)		•	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 260449US0X PCT		SERIAL NO. 10/511,273						
				APPLICANT									
LIST OF REFERENCES CITED BY APPLICANT			RENCES CITED BY AP	Kostas KOSMATOPOULOS, et al.									
					FILING DATE		GROUP						
					June 27, 2005		1643						
					U.S. PATENT DOCUMENTS								
EXAN	INER		DOCUMENT	I	SUB SHANG DATE			FILING DATE					
INIT			NUMBER	DATE	NAME	CLASS IF APPROPRIATE							
		AA				<u> </u>							
		AB				ļ							
		AC											
		AD				ļ <u>.</u>							
ļ		AE											
		AF											
		AG		<u> </u>									
		AH											
		_AI											
		AJ											
		AK											
		AL											
		AM											
<u> </u>		AN											
				FO	REIGN PATENT DOCUMENTS								
	4		DOCUMENT NUMBER	DATE	COUNTRY		YES	TRANSLATION NO					
		AO											
		AP											
		AQ											
		AR											
		AS											
		AT											
		AU											
ļ		AV											
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)													
46	LB AW Kessler et al, J. Exp. Med., 193(1): 73-88, 2001												
1		AX	Kawashima et al, Cancer Research, 59: 431-435, 1999										
		AY	Tahara et al, Clinical Cancer Research, 5: 2236-2241, 1999										
		AZ	Lu et al, Cancer Research, 60: 5223-5227, 2000 Additional References sheet(s) atta			erences sheet(s) attached							
Exami	ner	•	Jum Bu	(6)		Date Cor	sidered	10/6/07					
*Exam	iner: In mance	itial if r and no	eference is considered, ot considered. Include co	whether or not py of this form	citation is in conformance with MPEP 60 with next communication to applicant.	09; Draw lir	ne through	*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Docket No.

260449US0X PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Kostas KOSMATOPOU

SERIAL NO:

10/511,273

FILED:

June 27, 2005

FOR:

EPHA2 ANTIGEN T EPITOPES

GAU:

1643

EXAMINER: Bristol

INFORMATION DISCLOSURE EMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

07/24/2007 CNGUYEN2 00000089 10511273

95 EC:1869

189.99 OP

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Marina I. Miller, Ph.D.

Registration No. 59,091

Docket No. 260449US0X PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Kostas KOSMATOPOULO

SERIAL NO:

10/511,273

FILED: FOR: June 27, 2005

EPHA2 ANTIGEN T EPITOPES

GAU:

1643

EXAMINER: Bristol

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed
reference(s) are attached, where required, as are either statements of relevancy or any readily available English
translations of pertinent portions of any non-English language reference(s).

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be
related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies
of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the
attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

Marina I. Miller, Ph.D.

Registration No. 59,091

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Form PTO 1449		U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.			
(Modified)		PATENT AND TRADEMARK OFFICE	260449US0X PCT	10/511,273			
LIST OF	DEEE	DENICES CITED BY ADDITIONAL	APPLICANT				
LISTOF	KEFEF	RENCES CITED BY APPLICANT	Kostas KOSMATOPOULOS, et al.				
			FILING DATE	GROUP			
			June 27, 2005	1643			
			Including Author, Title, Date, Pertinent Pag	es, etc.)			
LBB AAA		Vonderheide et al, Clinical Cancer Re					
	AAB	Nemunaitis et al, Expert Opin. Biol. T	her., 7(1): 89-102, 2007				
	AAC	Gilboa, Nature Reviews Cancer, 4: 4	401-411, 2004				
	AAD	O'Mahony et al, Journal of Clinical O	ncology, 23(35): 9022-9028, 2005				
	AAE						
	AAF						
	AAG						
	аан			,			
	·AAI		,				
	AAJ						
	AAK						
	AAL						
	ААМ						
	AAN	·	•				
	AAO						
	AAP						
	AAQ						
Examiner	- TAT. 1 **	Lun Emyl		te Considered 10/6/07			
conformance	and no	ererence is considered, whether or no at considered. Include copy of this form	t citation is in conformance with MPEP 609; D n with next communication to applicant.	raw line through citation if not in			

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 260449US0X PCT		SERIAL NO. 10/511,273				
			APPLICANT 10/511,275					
LIST OF REFERENCES CITED BY APPLICANT			Kostas KOSMATOPOULOS, et al.					
				FILING DATE	<u> </u>	GROUP		
				June 27, 2005		1643		
				U.S. PATENT DOCUMENTS				
EXAMINER		DOCUMENT		I SOUTH A SOUT	1	SUB		ILING DATE
INITIAL		NUMBER	DATE	NAME CLASS CLASS FILING DAT				
	AA						-	
	AB							
	AC							
	AD	· · · · · · · · · · · · · · · · · · ·						
	AE							
	AF							
	AG AH							
	Al							
	AJ				!			
	AK				-		-	
	AL							
	AM							
<u> </u>	AN							····································
	7.1.4		FO	REIGN PATENT DOCUMENTS	<u> </u>	l .		
T T		TRANSLATION TRANSLATION		PLATION!				
		DOCUMENT NUMBER	DATE	COUNTRY		YE		NO NO
	AO							
	AP		· · · · · · · · · · · · · · · · · · ·			,		
	AQ	· · · · · · · · · · · · · · · · · · ·						
	AR							
	AS							
	AT							
	AU				····			
	AV					İ		
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)								
	AW	Kessler et al, J. Exp. Med., 193(1): 73-88, 2001						
	AX	Kawashima et al, Cancer Research, 59: 431-435, 1999						
	AY	Tahara et al, Clinical Cancer Research, 5: 2236-2241, 1999						
	AZ	Lu et al, Cancer Research, 60: 5223-5227, 2000 Additional References sheet(s) attach					sheet(s) attached	
Examiner			·	Date Considered ·				
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.		
(Modified)	PATENT AND TRADEMARK OFFICE	260449US0X PCT	10/511,273		
		APPLICANT			
LIST OF REFE	RENCES CITED BY APPLICANT	Kostas KOSMATOPOULOS, et al.			
		FILING DATE	GROUP		
		June 27, 2005	1643		
	OTHER REFERENCES (Including Author, Title, Date, Pertinent P	ages, etc.)		
AAA	Vonderheide et al, Clinical Cancer R	esearch, 7: 3343-3348, 2001			
AAB	Nemunaitis et al, Expert Opin. Biol. T	her., 7(1): 89-102, 2007			
AAC	Gilboa, Nature Reviews Cancer, 4: 4	401-411, 2004			
AAD	O'Mahony et al, Journal of Clinical O	ncology, 23(35): 9022-9028, 2005			
AAE					
AAF					
AAG					
ААН					
AAI					
AAJ					
AAK			:		
AAL					
ААМ					
AAN		,			
AAO	·				
ААР					
AAQ		·			
Examiner			Date Considered		
*Examiner: Initial if conformance and n	reference is considered, whether or no ot considered. Include copy of this form	t citation is in conformance with MPEP 609; n with next communication to applicant.	Draw line through citation if not in		